Peutz-Jeghers Syndrome (PJS) is a rare genetic disorder that is characterized by the presence of polyps in the gastrointestinal tract and dark spots on the skin. While the exact cause of PJS is unknown, research has suggested that it is caused by a genetic mutation. This article will explore the link between genetics and PJS, discussing the genetic mutation that is believed to cause the disorder, and the implications of this mutation for diagnosis and treatment.
Peutz-Jeghers Syndrome (PJS) is a rare genetic disorder that is characterized by the presence of polyps in the gastrointestinal tract and dark spots on the skin. The polyps are benign, meaning they are not cancerous, but they can cause problems with digestion and can lead to bleeding or blockages in the intestines. The dark spots are called “lentigines” and are caused by an increased number of melanocytes, the cells that produce pigment in the skin. PJS is usually diagnosed in childhood, but it can also be diagnosed in adulthood. The disorder is caused by a mutation in the STK11 gene, which is responsible for controlling cell growth. People with PJS have an increased risk of developing certain types of cancer, including colorectal, pancreatic, and gastric cancer.
The exact cause of PJS is unknown, but research has suggested that it is caused by a genetic mutation. The mutation occurs in the STK11 gene, which is responsible for controlling cell growth. People with PJS have an increased number of polyps in the gastrointestinal tract, as well as dark spots on the skin. The STK11 gene mutation is inherited in an autosomal dominant pattern, meaning that a person only needs one copy of the mutated gene to develop the disorder. People with PJS have a 50% chance of passing the mutated gene on to their children.
PJS can be difficult to diagnose, as the symptoms can be similar to other conditions. In order to diagnose PJS, doctors may perform genetic testing to look for the STK11 gene mutation. Additionally, doctors may perform an endoscopy or colonoscopy to look for the presence of polyps in the gastrointestinal tract. Once PJS is diagnosed, treatment typically involves monitoring the patient for any changes in the polyps or dark spots. Surgery may be recommended to remove any polyps that are causing problems. Additionally, people with PJS may be advised to undergo regular screening for certain types of cancer, as they are at an increased risk of developing these types of cancer.
Peutz-Jeghers Syndrome (PJS) is a rare genetic disorder that is caused by a mutation in the STK11 gene. This mutation is inherited in an autosomal dominant pattern, meaning that a person only needs one copy of the mutated gene to develop the disorder. PJS is characterized by the presence of polyps in the gastrointestinal tract and dark spots on the skin. Diagnosis of PJS involves genetic testing and endoscopy or colonoscopy, and treatment typically involves monitoring for changes in the polyps or dark spots, as well as regular screening for certain types of cancer.
1.
Electronic Sepsis Alerts; Reducing Plaques in Coronary Arteries
2.
Ivonescimab Tops Pembrolizumab in PD-L1-Positive, Advanced NSCLC
3.
Hereditary cancer has a rare and underreported cause.
4.
New imaging guidelines for head and neck cancers, a step toward practice change
5.
BMTs that are "half-matched" are effective in treating severe sickle cell disease.
1.
Oncolytic Adenoviruses Targeting PD-L1: Advancing Cancer Immunotherapy and Tumor Control
2.
Personalized Cancer Vaccines: The Next Frontier in Precision Oncology
3.
Essential Updates in Hematology in Daily Practice
4.
The Predictive Power of Theranostics in Palliative Neuroendocrine Tumor Management
5.
Importance of Early Detection in Oncology
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VII
2.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I
3.
Current Scenario of Cancer- The Incidence of Cancer in Men
4.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part IV
5.
A New Era in Managing Cancer-Associated Thrombosis
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation